EUVIMEDOpdag EUVIMED
Crossref

Will Continuous Glucose Monitoring Metrics Replace Hemoglobin A1c in Assessing the Risk of Retinopathy (and Other Complications) in Patients with Type 2 Diabetes?

Magdalena Walicka, Edward Franek

Clinical Diabetology · 2024

DOI: 10.5603/cd.101353 ↗

At a glance

Journal article in Clinical Diabetology, 2024. Written by Magdalena Walicka and 1 co-authors.

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Clinical Diabetology is a bimonthly, open access journal of scientific and educational profile, which was created by combining the scientific assumptions of Experimental and Clinical Diabetology (Diabetologia Doświadczalna i Kliniczna)

Cite

APA

Walicka, M., & Franek, E. (2024). Will Continuous Glucose Monitoring Metrics Replace Hemoglobin A1c in Assessing the Risk of Retinopathy (and Other Complications) in Patients with Type 2 Diabetes?. Clinical Diabetology. https://doi.org/10.5603/cd.101353

Vancouver

Walicka M, Franek E. Will Continuous Glucose Monitoring Metrics Replace Hemoglobin A1c in Assessing the Risk of Retinopathy (and Other Complications) in Patients with Type 2 Diabetes?. Clinical Diabetology. 2024. doi:10.5603/cd.101353

BibTeX
@article{Walicka2024,
  author = {Walicka, Magdalena and Franek, Edward},
  title = {Will Continuous Glucose Monitoring Metrics Replace Hemoglobin A1c in Assessing the Risk of Retinopathy (and Other Complications) in Patients with Type 2 Diabetes?},
  journal = {Clinical Diabetology},
  year = {2024},
  doi = {10.5603/cd.101353}
}
Start for free →